Novo Nordisk: partnership with UCSF in stem cells
(CercleFinance.com) - Novo Nordisk has formed with the University of California San Francisco (UCSF) an exclusive collaboration for which the first milestone in the development of human embryonic stem cell lines has already been reached, the Danish drugmaker said on Wednesday.
Since early May, the partners are working on deriving cell lines to define a new quality standard in production of stem cell-based therapies, Novo said.
The company said the development of grade stem cell lines in collaboration with UCSF has helped to expand the focus on serious chronic diseases beyond diabetes.
Together with Cornell University, Novo Nordisk has also made significant progress in developing an encapsulation device that will protect the beta cells that are transplanted into patients from attack by the immune system, it said.
Novo anticipates that the first clinical trial could be initiated in the next few years.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Since early May, the partners are working on deriving cell lines to define a new quality standard in production of stem cell-based therapies, Novo said.
The company said the development of grade stem cell lines in collaboration with UCSF has helped to expand the focus on serious chronic diseases beyond diabetes.
Together with Cornell University, Novo Nordisk has also made significant progress in developing an encapsulation device that will protect the beta cells that are transplanted into patients from attack by the immune system, it said.
Novo anticipates that the first clinical trial could be initiated in the next few years.
Copyright (c) 2018 CercleFinance.com. All rights reserved.